Boston Scientific Sinks 12% as Cyberattack Forces Guidance Cut: “A Challenging Year”
Boston Scientific shares fell 12% after cutting 2026 adjusted EPS guidance to $3.16-$3.18 from $3.28-$3.32, citing a cyberattack and slower business. Q3 sales were $5.14B, up 1.5%, beating estimates. CEO Mike Mahoney acknowledged a challenging year. The stock recovered to a 4% loss, trading at $43.26.
How this was made
The 30-second read
Why it matters
The guidance cut signals slower growth, likely prompting short‑term selling pressure and heightened scrutiny of cyber‑risk across the sector.
Market read
First report of a material guidance reduction for a large‑cap med‑tech firm, accompanied by a double‑digit stock move.
What to watch
Potential upside from pending Penumbra acquisition and long‑term demand for Watchman device.
Background
Boston Scientific reported Q3 sales of $5.14 bn (+1.5%) and adjusted EPS of $0.73, but cut its 2026 outlook due to an August cyberattack that halted plants for eight days.
Ticker impact
Boston Scientific cut its 2026 adjusted EPS guidance to $3.16‑$3.18, down from $3.28‑$3.32, after a cyberattack forced a sales decline, triggering a 12% share drop.
downward pressure as investors price in slower growth and potential lost sales recovery
The guidance reduction is a fresh, material disclosure for a large‑cap medical device company, and the share already fell 12% on the news.
Market effects
May weigh on other med‑tech peers as investors reassess cyber‑risk and growth forecasts.
U.S. healthcare sector could see modest pullback in the near term.
Limited to U.S. and global med‑tech investors monitoring supply‑chain disruptions.
Counterpoint
If the lost sales are temporary, the stock could rebound on a bounce‑back in Q4.
Key entities
- CompanyBoston Scientific
Medical device maker (ticker BSX) reporting guidance cut.
- ExecutiveMike Mahoney
CEO of Boston Scientific, quoted on the cyberattack impact.
